Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + paclitaxel polymer micelles + carboplatin conversion therapy in unresectable stage III lung squamous cell carcinoma
ChiCTR2500097154Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, paclitaxel and carboplatin in Pulmonary squamous cell carcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Surgical conversion rate and Event-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
cadonilimabpaclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500097154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097154.